TLR-based immune adjuvants.
This work describes the nature and strength of the immune response induced by various Toll-like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various ligands capable of triggering individual TLRs, and then focuses on the efficacy and safety of those agents for which clinical results are available.
Steinhagen
Folkert
F
Cancer and Inflammation Program, National Cancer Institute, Frederick, MD 21702, United States.
Kinjo
Takeshi
T
Bode
Christian
C
Klinman
Dennis M
DM
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects* / Q000494:pharmacology*; D006801:Humans; D051193:Toll-Like Receptors / Q000187:drug effects* / Q000276:immunology*; D014611:Vaccination / Q000009:adverse effects* / Q000379:methods*; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D051193:Toll-Like Receptors; D014612:Vaccines